A reusable localized surface plasmon resonance biosensor for quantitative detection of serum squamous cell carcinoma antigen in cervical cancer patients based on silver nanoparticles array

• DOI: 10.2147/ijn.s58499
• Publication Date: 2014-02-24T01:46:57Z
• Authors: Mingrong Xi; Qianying Zhao; Ruiqi Duan; Jialing Yuan; Yi Quan; Huan Yang
• Keywords: Medicine (General); Silver; Metal Nanoparticles; Reproducibility of Results; Uterine Cervical Neoplasms; Equipment Design; 02 engineering and technology; Surface Plasmon Resonance; 3. Good health; R5-920; Nanomedicine; International Journal of Nanomedicine; Antigens, Neoplasm; Case-Control Studies; Lab-On-A-Chip Devices; Biomarkers, Tumor; Carcinoma, Squamous Cell; Humans; Female; 0210 nano-technology; Serpins; Original Research

Squamous cell carcinoma antigen (SCCa), as a tumor biomarker, plays an important role in adjuvant diagnosis, treatment evaluation, and prognosis prediction for cervical cancer patients. Localized surface plasmon resonance (LSPR) technique based on noble metal nanoparticles bypasses the disadvantages of traditional testing strategies, in terms of free-labeling, short assay time, good sensitivity, and selectivity. Herein, we develop a novel and reusable LSPR biosensor for the detection of SCCa. First, a triangle-shaped silver nanoparticle array was fabricated using the nanosphere lithography method. Next, we investigated and verified the feasibility of amino coupling method using 11-mercaptoundecanoic acid (MUA) to form a functionalized chip surface with monoclonal anti-SCCa antibodies on the silver nanoparticles for distinct detection of SCCa. Different concentrations of SCCa were successfully tested in both buffer and human serum by the ultrasensitive and specific LSPR system, with a linear quantitative detection range of 0.1-1,000 pM under optimal conditions. With appropriate regeneration solution, for example 50 mM glycine-HCl (pH 2.0), the LSPR biosensor featured effective fabrication reproducibility, which reduced both production cost and testing time. Our study represents the first application of the LSPR biosensor in cervical cancer, and demonstrates that the rapid, simple, and reusable nanochip can serve as a potential alternative for clinical serological diagnosis of SCCa in cervical cancer patients.